Structured Abstract
Objective Determine age-specific infection fatality rates for COVID-19 to inform public health policies and communications that help protect vulnerable age groups.
Methods Studies of COVID-19 prevalence were collected by conducting an online search of published articles, preprints, and government reports. A total of 120 studies were reviewed in depth and screened, of which 34 studies satisfied the inclusion criteria and were included in the meta-analysis. Age-specific IFRs were computed using the prevalence data in conjunction with reported fatalities four weeks after the midpoint date of the study, reflecting typical lags in fatalities and reporting. Meta-regression procedures in Stata were used to analyze IFR by age.
Results Our analysis finds a exponential relationship between age and IFR for COVID-19. The estimated age-specific IFRs are very low for children and younger adults but increase progressively to 0.4% at age 55, 1.4% at age 65, 4.6% at age 75, and 15% at age 85. We find that differences in the age structure of the population and the age-specific prevalence of COVID-19 explain about 90% of the geographical variation in population IFR.
Discussion These results indicate that COVID-19 is hazardous not only for the elderly but also for middle-aged adults, for whom the infection fatality rate is two orders of magnitude greater than the annualized risk of a fatal automobile accident and far more dangerous than seasonal influenza. Moreover, the overall IFR for COVID-19 should not be viewed as a fixed parameter but as intrinsically linked to the age-specific pattern of infections. Consequently, public health measures to mitigate infections in older adults could substantially decrease total deaths.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received for this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study is a meta-analysis using information from publicly available studies (published articles, Medrxiv preprints, and government reports).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Updated meta-analysis to include recent seroprevalence studies disseminated as of September 25. Added explanatory notes to charts and tables. Supplemental materials updated.
Data Availability
This study is a meta-analysis using information from published articles, preprints, and government reports; all sources are listed in the bibliography with active URLs. The data and Stata code used in performing the meta-regression analysis are provided as Supplementary Materials.
